Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 4Phase 3 3Phase 1/2 3Phase 4 2

Status

Completed 4

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Lymphoma, B-Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Has results × Inotuzumab Ozogamicin × Clear all
NCT01925131 2023-05-03

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

SWOG Cancer Research Network

Phase 1 Completed
50 enrolled 14 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01055496 2019-08-02

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Pfizer

Phase 1 Completed
103 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00724971 2019-03-15

Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab

Pfizer

Phase 1 Completed
10 enrolled 13 charts
Lymphoid

Lymphoma, B-Cell

NCT00073749 2018-12-17

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Pfizer

Phase 1 Completed
79 enrolled 24 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡